Research Analysts’ Recent Ratings Updates for 4D Molecular Therapeutics (FDMT)

A number of research firms have changed their ratings and price targets for 4D Molecular Therapeutics (NASDAQ: FDMT):

• 1/18/2025 – 4D Molecular Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 1/13/2025 – 4D Molecular Therapeutics had its price target lowered by analysts at Morgan Stanley from $8.00 to $6.00. They now have an “underweight” rating on the stock.
• 1/13/2025 – 4D Molecular Therapeutics had its price target lowered by analysts at Leerink Partners from $31.00 to $27.00. They now have an “outperform” rating on the stock.
• 1/13/2025 – 4D Molecular Therapeutics was downgraded by analysts at BMO Capital Markets from an “outperform” rating to a “market perform” rating. They now have a $15.00 price target on the stock, down previously from $40.00.
• 1/13/2025 – 4D Molecular Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
• 12/18/2024 – 4D Molecular Therapeutics had its price target lowered by analysts at Bank of America Co. from $79.00 to $46.00. They now have a “buy” rating on the stock.

4D Molecular Therapeutics Trading Down 1.6 %

NASDAQ FDMT traded down $0.08 during trading on Wednesday, reaching $4.60. The company’s stock had a trading volume of 212,140 shares, compared to its average volume of 756,777. The business has a 50-day moving average price of $6.52 and a 200-day moving average price of $11.19. 4D Molecular Therapeutics, Inc. has a 1-year low of $4.48 and a 1-year high of $36.25. The stock has a market capitalization of $212.43 million, a PE ratio of -1.61 and a beta of 2.81.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Marquette Asset Management LLC bought a new stake in shares of 4D Molecular Therapeutics in the 4th quarter valued at about $116,000. Barclays PLC lifted its holdings in 4D Molecular Therapeutics by 141.0% during the 3rd quarter. Barclays PLC now owns 114,848 shares of the company’s stock valued at $1,241,000 after purchasing an additional 67,202 shares during the last quarter. Y Intercept Hong Kong Ltd lifted its holdings in 4D Molecular Therapeutics by 81.3% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 24,538 shares of the company’s stock valued at $265,000 after purchasing an additional 11,002 shares during the last quarter. State Street Corp lifted its holdings in shares of 4D Molecular Therapeutics by 1.8% during the third quarter. State Street Corp now owns 2,116,508 shares of the company’s stock worth $22,879,000 after buying an additional 37,232 shares in the last quarter. Finally, Redmile Group LLC lifted its holdings in shares of 4D Molecular Therapeutics by 17.6% during the third quarter. Redmile Group LLC now owns 1,262,090 shares of the company’s stock worth $13,643,000 after buying an additional 188,655 shares in the last quarter. Institutional investors and hedge funds own 99.27% of the company’s stock.

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.